278 related articles for article (PubMed ID: 30037365)
1. MiR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition.
Cao L; Wan Q; Li F; Tang CE
BMB Rep; 2018 Sep; 51(9):456-461. PubMed ID: 30037365
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
3. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
[TBL] [Abstract][Full Text] [Related]
4. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
[TBL] [Abstract][Full Text] [Related]
6. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
Zhu X; Shen H; Yin X; Long L; Chen X; Feng F; Liu Y; Zhao P; Xu Y; Li M; Xu W; Li Y
Oncotarget; 2017 Jun; 8(24):39154-39166. PubMed ID: 28388577
[TBL] [Abstract][Full Text] [Related]
7. miR-874-3p mitigates cisplatin resistance through modulating NF-κB/inhibitor of apoptosis protein signaling pathway in epithelial ovarian cancer cells.
Wang Y; Yan C; Qi J; Liu C; Yu J; Wang H
Mol Cell Biochem; 2022 Jan; 477(1):307-317. PubMed ID: 34716858
[TBL] [Abstract][Full Text] [Related]
8. miR-146b promotes cell proliferation and increases chemosensitivity, but attenuates cell migration and invasion via FBXL10 in ovarian cancer.
Yan M; Yang X; Shen R; Wu C; Wang H; Ye Q; Yang P; Zhang L; Chen M; Wan B; Zhang Q; Xia S; Lu X; Shao G; Zhou X; Yu J; Shao Q
Cell Death Dis; 2018 Nov; 9(11):1123. PubMed ID: 30409964
[TBL] [Abstract][Full Text] [Related]
9. Snail Driving Alternative Splicing of CD44 by ESRP1 Enhances Invasion and Migration in Epithelial Ovarian Cancer.
Chen L; Yao Y; Sun L; Zhou J; Miao M; Luo S; Deng G; Li J; Wang J; Tang J
Cell Physiol Biochem; 2017; 43(6):2489-2504. PubMed ID: 29131012
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD.
Chen Y; Ke G; Han D; Liang S; Yang G; Wu X
Exp Cell Res; 2014 Jan; 320(1):12-20. PubMed ID: 24183997
[TBL] [Abstract][Full Text] [Related]
11. Core fucosylation of copper transporter 1 plays a crucial role in cisplatin-resistance of epithelial ovarian cancer by regulating drug uptake.
Lv X; Song J; Xue K; Li Z; Li M; Zahid D; Cao H; Wang L; Song W; Ma T; Gu J; Li W
Mol Carcinog; 2019 May; 58(5):794-807. PubMed ID: 30614075
[TBL] [Abstract][Full Text] [Related]
12. miR-98-5p contributes to cisplatin resistance in epithelial ovarian cancer by suppressing miR-152 biogenesis via targeting Dicer1.
Wang Y; Bao W; Liu Y; Wang S; Xu S; Li X; Li Y; Wu S
Cell Death Dis; 2018 May; 9(5):447. PubMed ID: 29670086
[TBL] [Abstract][Full Text] [Related]
13. miR-25-3p reverses epithelial-mesenchymal transition via targeting Sema4C in cisplatin-resistance cervical cancer cells.
Song J; Li Y
Cancer Sci; 2017 Jan; 108(1):23-31. PubMed ID: 27743413
[TBL] [Abstract][Full Text] [Related]
14. A Feedback Loop Between miR-30a/c-5p and DNMT1 Mediates Cisplatin Resistance in Ovarian Cancer Cells.
Han X; Zhen S; Ye Z; Lu J; Wang L; Li P; Li J; Zheng X; Li H; Chen W; Li X; Zhao L
Cell Physiol Biochem; 2017; 41(3):973-986. PubMed ID: 28222434
[TBL] [Abstract][Full Text] [Related]
15. miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin.
Guo P; Xiong X; Zhang S; Peng D
Oncol Rep; 2016 Dec; 36(6):3552-3558. PubMed ID: 27748936
[TBL] [Abstract][Full Text] [Related]
16. miR-15b regulates cisplatin resistance and metastasis by targeting PEBP4 in human lung adenocarcinoma cells.
Zhao Z; Zhang L; Yao Q; Tao Z
Cancer Gene Ther; 2015 Apr; 22(3):108-14. PubMed ID: 25721211
[TBL] [Abstract][Full Text] [Related]
17. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
[TBL] [Abstract][Full Text] [Related]
18. miR-200c overexpression inhibits the invasion and tumorigenicity of epithelial ovarian cancer cells by suppressing lncRNA HOTAIR in mice.
Yang C; Li H; Zhang T; Chu Y; Chen D; Zuo J
J Cell Biochem; 2020 Feb; 121(2):1514-1523. PubMed ID: 31535411
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-520g promotes epithelial ovarian cancer progression and chemoresistance via DAPK2 repression.
Zhang J; Liu L; Sun Y; Xiang J; Zhou D; Wang L; Xu H; Yang X; Du N; Zhang M; Yan Q; Xi X
Oncotarget; 2016 May; 7(18):26516-34. PubMed ID: 27049921
[TBL] [Abstract][Full Text] [Related]
20. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R.
Zhang Y; Huang S; Guo Y; Li L
Biomed Pharmacother; 2018 Oct; 106():1357-1363. PubMed ID: 30119207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
